Webinar 4:
Thursday, April 2, 2009
12 pm ET • 90 minutes
Clinical Case Studies: How Biomarkers Can Help Make a Go/No-go Decision
about Proceeding with a Drug Development Program

Biomarkers can be used as a pharmacodynamic tool, to enrich patient populations for clinical trials, to help prioritize a drug portfolio, and in some cases, as companion diagnostics. This panel will discuss the critical factors in designing and implementing a biomarker strategy.

FEATURING:

Richard LaLonde , PharmD, FCP, FAAPS VP & Global Head of Clinical Pharmacology Pfizer	Eric Rubin, MD VP Oncology Clinical Research Merck Research Laboratories
Lewis Bender CEO Interleukin Genetics	Julian Adams President of R&D & Chief Scientific Officer Infinity Pharmaceuticals, Inc.

Join us for a thought-provoking analysis of this evolving concept! Grab your team, a phone and a computer with Web access (that last one's optional). No travel required.

Audio recording only: $499

REGISTER

Register for the live webinar, the live webinar PLUS the audio recording or the audio recording only!

Back to top
______________________________________________________________________

dhover.custcare@elsevier.com.

FDC-Windhover
Elsevier Business Intelligence
P.O. Box 7247
Philadelphia, PA 19101-9257
* Tel: +1 (800) 332-2181 (U.S.)
or +1 (908) 547-2159 (International)
* Fax: +1 (908) 547-2165FDC-Windhover
P.O. Box 7247
Philadelphia, PA 19101-9257
* Tel: +1 (800) 332-2181
* Fax: +1 (908) 547-2165